AllAnalyst Report
logoMorningstarOctober 29, 2020

Gilead Sciences, Inc.: Lowering Our Gilead FVE to $75 After Q3; Maintaining Our Veklury Forecast, but Lowering Jyseleca

Symbols
GILD
Sector(s)
Healthcare
Rating
Premium
Current Price
$61.37
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE